Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Molidustat (BAY85-3934) for Anemia in Pre-dialysis CKD (DIALOGUE 1)
NCT02021370Phase 2Completed
- Sponsor
- Bayer
- Start
- Feb 2014
- Primary completion
- Sep 2015
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 2, randomised, double-blind trial of molidustat in anemia of chronic kidney disease (CKD-A) (6 arms), sponsored by Bayer. Primary endpoint: Change in local laboratory hemoglobin level from baseline to the average during the last 4 weeks treatment period at 16 weeks. Started Feb 2014; status: completed.
02
Drugs
molidustat
03
Conditions
anemia of chronic kidney disease (CKD-A)
Beyond the preview
Go deeper on NCT02021370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02021370.